First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Hyun Cheol, Bang, Yung-Jue, S Fuchs, Charles, Qin, Shu-Kui, Satoh, Taroh, Shitara, Kohei, Tabernero, Josep, van Cutsem, Eric, Alsina, Maria, Cao, Zhu Alexander, Lu, Jia, Bhagia, Pooja, Shih, Chie-Schin, Janjigian, Yelena Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411394/
https://www.ncbi.nlm.nih.gov/pubmed/33167735
http://dx.doi.org/10.2217/fon-2020-0737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411394/
https://www.ncbi.nlm.nih.gov/pubmed/33167735
http://dx.doi.org/10.2217/fon-2020-0737

Ejemplares similares